Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overcoming a bid by Biogen to ...

Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's offering.This Tysabri (natalizumab) market report delivers an ...

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

The authors of a review article on the future of ustekinumab biosimilars for treating Crohn disease (CD) discussed key ...

Regulatory applications seeking approval for a biosimilar referencing Tysabri have been approved in both the United States and Europe. A Tysabri biosimilar is now available in some European ...

A key trend in the tysabri (natalizumab) market is the growing focus on biosimilars, which offer cost-effective alternatives to branded drugs like Tysabri. In January 2024, Sandoz launched Tyruko ...